目的：探讨C12部分肿瘤标志物联合检测在胃癌化疗疗效评价中的价值。方法：应用C12多肿瘤标志物蛋白芯片检测系统检测90例胃癌患者化疗前后血清中部分肿瘤标志物水平变化，探寻出评价胃癌化疗疗效的有效性指标。结果：在临床疗效评价为CR，PR的患者化疗后CA199，CA242，CEA，CA125，AFP等水平较化疗前明显下降，差异有显著性（P＜0.05）。临床疗效为SD的患者化疗前后肿瘤标志物水平无明显变化（P>0.05），PD的患者化疗后肿瘤标志物检测值较化疗前明显升高，差异有显著性（P<0.05），C12部分肿瘤标志物单独检测与临床客观疗效评价的符合率分别为CA19947.7%，CA24243.3%，CEA38.8%，CA12523.3%AFP 16.6%， C12部分肿瘤标志物联合检测与临床客观疗效的符合率为68.8%，高于单项检测的符合率，差异有显著性（P<0.05）。结论：C12多肿瘤标志物部分联合检测可作为胃癌化疗疗效的评价指标。%To explore the clinical value of tumor markets biochip diagnostic system C12 in the objective response of chemotherapy of the gastric cancer Methods: The serum of 90 pathologically combirmed gastric cancer patients for parts tumor markets of the C12 had been detected before and after chemotherapy . we explored the values of combined measures and efficacy evaluation on gastric cancer . Results: The dates of CA199、CA242、CEA、CA125、AFP after chemotherapy had significant decreased compared with dates before chemotherapy in CR、PR . There were statistical significance (P<0 . 05). The dates of tumor markets in SD had no significant difference before and after chemotherapy. The dates of tumor markets in PD after chemotherapy had significantly increased compared with dates before chemotherapy . The difference was statistic significant (P<0 . 05). The consistency rates of part tumor markets with objective response were CA199 47.7%,CA242 43.3%,CEA 38.8%,CA125 23.3% AFP 16.6%,respectively. The part combined detection of biochip diagnose system C12 after chemotherapy effects of the gastric cancers could corresponded 68.8% with objective tumor response,The combined response were higher than single detective response (P<0.05). Conclusion: The combine detections of part tumor markets biochip diagnostic system C12 could estimated chemotherapy response .
展开▼
